Carillon Tower Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Carillon Tower Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$3.36M	Sell	72,136 -3,700	-5%	-$173K	0.02%	439
2020 Q3	$3.22M	Buy	75,836 +25,540	+51%	+$1.12M	0.04%	377
2020 Q2	$2.41M	Sell	50,296 -1,200	-2%	-$59.9K	0.02%	425
2020 Q1	$2.37M	Sell	51,496 -5,500	-10%	-$276K	0.02%	392
2019 Q4	$3.42M	Sell	56,996 -1,900	-3%	-$113K	0.02%	423
2019 Q3	$3.33M	Sell	58,896 -500	-0.8%	-$28.1K	0.02%	428
2019 Q2	$3.31M	Buy	59,396 +5,900	+11%	+$308K	0.02%	428
2019 Q1	$2.7M	Buy	53,496 +300	+0.6%	+$13.3K	0.02%	434
2018 Q4	$2.14M	Buy	53,196 +10,700	+25%	+$551K	0.02%	428
2018 Q3	$2.95M	Buy	+42,496	New	+$3.22M	0.02%	398

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Carillon Tower Advisers's EGRX Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Eagle Pharmaceuticals, Inc. (EGRX) stake by 4.9% in Q4 2020, selling an estimated $173K and leaving 72,136 shares worth $3.36M. The position accounts for 0.02% of the portfolio, ranked #439.

Carillon Tower Advisers first reported a position in EGRX in Q3 2018 and has held it in 10 quarters since. The position peaked at $3.42M in Q4 2019. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

Carillon Tower Advisers held 72,136 shares of Eagle Pharmaceuticals, Inc. worth $3.36M as of Q4 2020.
Carillon Tower Advisers sold 3,700 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $173K.
Eagle Pharmaceuticals, Inc. made up 0.02% of Carillon Tower Advisers's portfolio in Q4 2020, its #439 holding.
Carillon Tower Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and has held it in 10 quarters since.
Carillon Tower Advisers's Eagle Pharmaceuticals, Inc. position peaked at $3.42M in Q4 2019.
166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.